Odyssey Therapeutics Stock

odysseytx.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $492.23MM

Odyssey Therapeutics aims to create precision medicines for patients with cancer or inflammatory health issues.

Register To Buy and Sell Shares

For more details on financing and valuation for Odyssey Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Odyssey Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Odyssey Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Odyssey Therapeutics investors also invested in these private companies

HBM Healthcare Investments
Alexandria Venture Investments
Foresite Capital Management
AB Magnitude Ventures Group
BlackMars Capital
Global BioAccess Fund
Colt Ventures
Creacion Ventures
SR One Capital Management
HBM Partners


Management Team

Gary Glick Ph.D
Founder, Chief Executive Officer & President
Joseph McDonald Ph.D
Chief Data Officer
Will Smiley
Head of Human Resources
David Pompliano Ph.D
Co-Founder & Chief Innovation Officer
Collin Todd
Vice President of Strategy & Business Development
Kira Schwartz JD
Executive Vice President, General Counsel & Secretary
Robert Abraham Ph.D
Executive Vice President, Cancer Biology
Natalie Dales Ph.D
Chief of Research Operations & Portfolio Strategy
Luigi Franchi M.D., Ph.D
Senior Vice President, Head Of Immunology
Anthony Opipari M.D., Ph.D
Senior Vice President, Translational Medicinee
Darryl Patrick D.V.M., Ph.D
Executive Vice President, Nonclinical Development
Steve Soisson, Ph.D.
Executive Vice President, Structural Biology & Protein Therapeutics
Jeffrey Hermes Ph.D
Executive Vice President, Enabling Sciences
Shifeng Pan Ph.D
Executive Vice President, Head Of Discovery

Board Members

Jeffrey M. Leiden M.D., Ph.D
Charles Baum M.D., Ph.D
Mirati Therapeutics
Jill Carroll
SR One Capital Management
Carl L. Gordon Ph.D, CFA

Frequently Asked Questions About Odyssey Therapeutics’ Stock

Can you buy Odyssey Therapeutics’ stock?
Odyssey Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Odyssey Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Odyssey Therapeutics’ stock?
Yes, you can sell stock of a private company like Odyssey Therapeutics. Forge can help you sell your Odyssey Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Odyssey Therapeutics’ stock price?
Odyssey Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Odyssey Therapeutics’ private market stock price with Forge Data.
What is Odyssey Therapeutics’ stock ticker symbol?
Odyssey Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Odyssey raises epic $101M to push programs off to clinical sea
Odyssey Therapeutics has raised a $101 million Series C to help get its next-gen precision immunomodulators and oncology medicines into the clinic. The newest financing round was led by Ascenta Capital and brings the Boston-based biotech’s total raised to $487 million since launching in 2021. The new funds will be channeled to support the advancement of multiple programs into clinical studies, several of which could enter human trials within the next year, Odyssey CEO and founder Gary Glick, Ph.D., said in a Dec. 5 release.
Updated on: Apr 13, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.